1. Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice. (17th November 2021) Authors: Ruggiero, A.; Fabbrocini, G.; Cinelli, E.; Ocampo Garza, S. S.; Camela, E.; Megna, M. Journal: Clinical and experimental dermatology Issue: Volume 47:Number 3(2022) Page Start: 561 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice. (1st March 2022) Authors: Ruggiero, A.; Fabbrocini, G.; Cinelli, E.; Ocampo Garza, S. S.; Camela, E.; Megna, M. Journal: Clinical and experimental dermatology Issue: Volume 47:Number 3(2022) Page Start: 561 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Apremilast efficacy and safety in elderly psoriasis patients over a 48‐week period. (28th July 2020) Authors: Megna, M.; Fabbrocini, G.; Camela, E.; Cinelli, E. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 11(2020) Page Start: e705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Nail changes as manifestation of systemic disease in COVID‐19 infection. (28th April 2021) Authors: Ocampo‐Garza, S.S.; Ocampo‐Candiani, J.; Camela, E.; Vastarella, M.; Fabbrocini, G.; Scalvenzi, M.; Villani, A. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 8(2021) Page Start: e474 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Real‐life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2‐year period. (1st October 2020) Authors: Megna, M.; Camela, E.; Cinelli, E.; Fabbrocini, G. Journal: Clinical and experimental dermatology Issue: Volume 45:Number 7(2020) Page Start: 848 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Real‐life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2‐year period. (2nd June 2020) Authors: Megna, M.; Camela, E.; Cinelli, E.; Fabbrocini, G. Journal: Clinical and experimental dermatology Issue: Volume 45:Number 7(2020) Page Start: 848 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Reply to 'New‐onset cutaneous lichen planus triggered by COVID‐19 vaccination' by Merhy et al. (17th December 2021) Authors: Camela, E.; Guerrasio, G.; Patruno, C.; Scalvenzi, M.; Di Caprio, N.; Fabbrocini, G.; Napolitano, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 4(2022) Page Start: e249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗